Neuropsychiatric symptom burden in early-onset and late-onset Alzheimer's disease as a function of age
- PMID: 38958543
- PMCID: PMC11350043
- DOI: 10.1002/alz.14042
Neuropsychiatric symptom burden in early-onset and late-onset Alzheimer's disease as a function of age
Abstract
Introduction: We examined the burden of neuropsychiatric symptoms (NPSs) in early-onset (EO) and late-onset (LO) Alzheimer's disease (AD) and adjusted for age effects via the inclusion of cognitively unimpaired (CU) individuals.
Methods: Cross-sectional data from 2940 EOAD, 8665 LOAD, and 8775 age-stratified CU individuals (early-CU, n = 2433; late-CU, n = 6342) from the National Alzheimer's Coordinating Center database were included. Fisher's exact tests compared EOAD and LOAD on the presence and severity of NPSs. Multiple logistic regression models included an age*diagnosis interaction to examine age effects.
Results: Presence (ps < 0.0001) and severity (ps < 0.05) of NPS were greater in EOAD than in LOAD. However, after adjusting for base rates in NPS in CU individuals (age effects), only elation and eating behaviors were more frequent in EOAD (ps < 0.05) and nighttime behaviors more frequent and severe in LOAD (ps < 0.05).
Discussion: Few NPSs were specific to the EOAD versus LOAD. Previous findings of greater NPS burden in EOAD may partially reflect age effects.
Highlights: Adjusting for age effect, elation and eating problems are more frequent in EOAD. Adjusting for age effect, sleep disturbances are more frequent and severe in LOAD. Age effects underlie higher neuropsychiatric symptom presentation in EOAD than in LOAD.
Keywords: behavioral and psychological symptoms in dementia; early‐onset Alzheimer's disease; late‐onset Alzheimer's disease; neuropsychiatric symptoms.
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Conflict of interest statement
None of the authors has any conflicts of interest to report. L.G.A. has provided consultation to Eli Lilly, Biogen, Two Labs, FL Department of Health, Genentech, NIH Biobank, GE Healthcare, Eisai, Roche Diagnostics, and Alnylam. L.G.A. receives the following research support: NIA U01 AG057195, NIA R01 AG057739, NIA P30 AG010133, Alzheimer's Association LEADS GENETICS 19‐639372, Alzheimer's Association SG‐23‐1061716, Roche Diagnostics RD005665, AVID Pharmaceuticals, Life Molecular Imaging. L.G.A. has received honoraria for serving on independent data safety monitoring boards and providing educational CME lectures and programs. L.G.A. has stock in Cassava Sciences. Author disclosures are available in the Supporting information.
Figures


References
-
- Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA. Early‐versus late‐onset Alzheimer's disease: more than age alone. J Alzheimers Dis. 2010;19(4):1401‐1408. - PubMed
-
- Isik AT, Soysal P, Solmi M, Veronese N. Bidirectional relationship between caregiver burden and neuropsychiatric symptoms in patients with Alzheimer's disease: a narrative review. Int J Geriatr Psychiatry. 2019;34(9):1326‐1334. - PubMed
Publication types
MeSH terms
Grants and funding
- P30 AG066518/AG/NIA NIH HHS/United States
- P50 AG005142/AG/NIA NIH HHS/United States
- R37 AG057739/AG/NIA NIH HHS/United States
- P50 AG047266/AG/NIA NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- P50 AG025688/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- P20 AG068077/AG/NIA NIH HHS/United States
- P50 AG033514/AG/NIA NIH HHS/United States
- P30 AG013854/AG/NIA NIH HHS/United States
- P30 AG053760/AG/NIA NIH HHS/United States
- P20 AG068082/AG/NIA NIH HHS/United States
- P30 AG066444/AG/NIA NIH HHS/United States
- LDRFP-21-818464/ALZ/Alzheimer's Association/United States
- P30 AG010124/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- P20 AG068053/AG/NIA NIH HHS/United States
- P50 AG005131/AG/NIA NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- U01 AG057195/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- P50 AG005146/AG/NIA NIH HHS/United States
- U24 AG072122/AG/NIA NIH HHS/United States
- P30 AG035982/AG/NIA NIH HHS/United States
- P50 AG008702/AG/NIA NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P30 AG013846/AG/NIA NIH HHS/United States
- P50 AG047270/AG/NIA NIH HHS/United States
- P30 AG072980/AG/NIA NIH HHS/United States
- P50 AG005136/AG/NIA NIH HHS/United States
- P30 AG049638/AG/NIA NIH HHS/United States
- P30 AG012300/AG/NIA NIH HHS/United States
- P30 AG062422/AG/NIA NIH HHS/United States
- P50 AG016573/AG/NIA NIH HHS/United States
- P50 AG005134/AG/NIA NIH HHS/United States
- P30 AG008017/AG/NIA NIH HHS/United States
- P30 AG066546/AG/NIA NIH HHS/United States
- P50 AG005138/AG/NIA NIH HHS/United States
- P50 AG047366/AG/NIA NIH HHS/United States
- P20 AG068024/AG/NIA NIH HHS/United States
- P30 AG072958/AG/NIA NIH HHS/United States
- P30 AG072976/AG/NIA NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- P30 AG019610/AG/NIA NIH HHS/United States
- P30 AG072947/AG/NIA NIH HHS/United States
- P30 AG072959/AG/NIA NIH HHS/United States
- P30 AG028383/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical